About: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 April 1994

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у квітні 1994 (uk) artículu científicu espublizáu n'abril de 1994 (ast) scientific article published on 01 April 1994 (en) im April 1994 veröffentlicher wissenschaftlicher Artikel (de)
publication date	wds:Q72512349-D7706D5B-5E53-4EF0-A088-749D197B4420
publication date	1994-04-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q72512349-016C8A94-D66F-44DD-825A-EDAD77A7831C wds:Q72512349-67C597BE-4A97-4905-B840-E7AAF84606C3
author name string	Henry DH Abels RI
rdfs:label	Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies (en) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies (nl)
skos:prefLabel	Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies (en) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies (nl)
name	Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies (en) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies (nl)
title	wds:Q72512349-FB7885E5-EE13-4FD8-871D-60A22FEFA9C3
title	Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies (en)
page(s)	wds:Q72512349-EFF8C1D1-5F5C-40CC-BA0F-871D54A7F38B
page(s)	21-28
instance of	wds:Q72512349-3D02F7B7-0B38-4121-B0AE-BF38DAF5DD05
instance of	scholarly article
main subject	wds:Q72512349-B910D246-0282-4B07-A2F5-69527A3660B0
main subject	chemotherapy
PubMed ID	wds:Q72512349-009BC0E4-54CF-4517-A03D-6E9D430AACA8
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8202722
PubMed ID	8202722
published in	wds:Q72512349-AEA052C5-61A1-4539-AB12-715462CEF279
published in	Seminars in Oncology
issue	wds:Q72512349-30EE1D6E-5217-4ADC-9502-20C7C5E2B14A
volume	wds:Q72512349-DB8EF133-18E1-4C2B-A2ED-56D0AC64A7C3
issue	2 Suppl 3
volume	21
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q72512349
is cites work of	Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy Impact of epoetin beta on quality of life in patients with malignant disease Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report Controversies in selection of epoetin dosages. Issues and answers Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer Clinical and economic impact of epoetins in cancer care Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia A novel combination of four flavonoids derived from Astragali Radix relieves the symptoms of cyclophosphamide-induced anemic rats. Recombinant human erythropoietin (rhEPO) in the prevention and treatment of chemotherapy-induced anaemia Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer Restrictive allogeneic blood transfusion strategy in patients with extremity bone sarcomas Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis Health-related quality of life in patients with iron deficiency anemia: impact of treatment with intravenous iron Haemopoietic growth factors in paediatric oncology: a review of the literature
is cites work of	wds:Q24240202-78C1A7D4-6E46-4956-94F4-C84916246DB7 wds:Q37452747-467D3436-327F-41CF-B6A0-170B5F8E9067 wds:Q35938500-326701C4-746D-4F08-8870-965505360EA5 wds:Q24306910-70F6032F-84A2-427B-AC10-68E848C40855 wds:Q40549841-C74F51E1-3670-4F65-8A10-37FE6CCFB799 wds:Q77571467-8000AA65-428C-41A8-B059-BFBE95643414 wds:Q92151520-AEAF4E05-7639-4F7C-9A46-9195AAF99FCE wds:Q28362979-B01FE738-4D1E-4BEE-AB47-EEA55E569D3A wds:Q36115014-5C68465B-9738-4C93-AC41-54C28D8D3F9C wds:Q38130141-B3F3C3B0-A2F4-44DC-A4D9-E3D56F2F5F74 wds:Q40513398-C27C1E48-5F2E-43F7-A0CC-BC63DDB2CBEA wds:Q36646758-4D70660E-2930-49F7-B394-BFC3ADF0F28B wds:Q34222508-DBCD804B-59FE-4B83-9A9B-4A4419C43C04 wds:Q36410646-B96346A1-7FC5-46D1-AA99-48C30DCB4297 wds:Q42199446-48ADE250-4994-4E40-87A7-5B009F328383 wds:Q36624004-7A366EE9-7B61-4C8F-8B58-5A28E5E352A8 wds:Q30803363-CAACE9AB-09E1-475C-9AEA-FB5905B43C9E wds:Q58700922-E00976BB-DA4B-472F-90B6-43ED0A095A06 wds:Q28362989-3E89C958-B0C2-46F2-97CD-B5B252258DCF wds:Q33336925-B78B8FCA-23A3-4CD9-8831-BCD35DA16DF3 wds:Q74563149-44B422B9-3245-4DEC-A6FA-2E0379FFBB74

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software